Zoledronic acid + Standard Therapy
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
First or Second Line HER2-negative Breast Cancer
Conditions
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Trial Timeline
Jun 1, 2010 → Aug 1, 2012
NCT ID
NCT01129336About Zoledronic acid + Standard Therapy
Zoledronic acid + Standard Therapy is a approved stage product being developed by Novartis for First or Second Line HER2-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01129336. Target conditions include First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01129336 | Approved | Completed |
Competing Products
12 competing products in First or Second Line HER2-negative Breast Cancer